Early diagnosis of Parkinson's disease and initiation of treatment

Reviews in Neurological Diseases

Volumn 5, Issue 2, 2008, Pages 47-55

  Weiner, William J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bradykinesia; Diagnosis; Dopamine receptor agonists; Levodopa carbidopa; MAO B inhibitors; Parkinson's disease; Rigidity; Tremor

Indexed keywords

AMANTADINE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOT DERIVATIVE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NEUROPROTECTIVE AGENT; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOCOPHEROL; TRIHEXYPHENIDYL;

BLURRED VISION; BRADYKINESIA; CONFUSION; DYSKINESIA; EARLY DIAGNOSIS; EDEMA; FATIGUE; FOOT EDEMA; HALLUCINATION; HEADACHE; HUMAN; LIVEDO RETICULARIS; MEMORY DISORDER; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; PERSONALITY DISORDER; REVIEW; SLEEP DISORDER; SOMNOLENCE; TREMOR; URINARY HESITANCY; VISUAL HALLUCINATION; VOMITING; XEROSTOMIA;

EARLY DIAGNOSIS; HUMANS; PARKINSON DISEASE;

EID: 46749092548     PISSN: 15452913     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Weiner WJ. A differential diagnosis of Parkinsonism. Rev Neurol Dis. 2005;2:124-131.
2. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson's disease. Arch Neurol. 1993;50:140-148.
3. Uitti RJ, Baba Y, Whaley NR, et al. Parkinson disease: handedness predicts asymmetry. Neurology. 2005;64:1925-1930.
4. Poewe WH, Wenning GR. The natural history of Parkinson's disease. Ann Neurol. 1998;44:S1-S9.
5. Suchowersky O, Reich S, Perlmutter J, et al. Practice parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review). Neurology. 2006;66:968-975.
6. Riley D, Lang AE, Blair RD, et al. Frozen shoulder and other shoulder disturbances in Parkinson's disease. J Neurol Psychiatry. 1989;52:63-66.
7. Shulman LM, Singer C, Bean JA, Weiner WJ. Internal tremor in patients with Parkinson's disease. Mov Disord. 1996;11:3-7.
8. Shulman LM, Anderson KE, Gruber-Baldini A, et al. Disease specific or co-morbid factors: which has the greatest impact on quality of life in Parkinson's disease? Neurology. 2006(Suppl 2):A116.
9. Shulman LM, Anderson KE, Gruber-Baldini A, et al. Disease specific or co-morbid factors: which has the greatest impact on disability in Parkinson's disease? Mov Disord. 2006;21(Suppl 15):SS09.
10. Aminoff MJ. Treatment should not be initiated too soon in Parkinson's disease. Ann Neuro. 2006;59:562-564.
11. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol. 2006;59:559-562.
12. Kurlan R. "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology. 2005;64:923-924.
13. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
14. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol. 1996;40:37-45.
15. Marras C, McDermott MP, Rochon PA, et al. Parkinson Study Group. Survival in Parkinson disease: thirteen-year follow-up on the DATATOP cohort. Neurology. 2005;11:64:87-93.
16. Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter initiation of treatment for Parkinson's disease: an evidence based review. Neurology. 2002;58:11-17.
17. Waters CH, Sethi KD, Hauser RA, et al; Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study. Mov Disord. 2004;19:426-432.
18. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
19. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
20. Parkinson Study Group. A controlled randomized, delayed-start of rasagiline in early Parkinson disease. Arch Neurol. 2004;61:561-566.
21. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modifications of parkinsonism. N Engl J Med. 1967;276:374-379.
22. Weiner WJ. The initial treatment of Parkinson's disease should begin with levodopa. Mov Disord. 1999;14:716-724.
23. Factor SA. Parkinson's Disease: Initial treatment with levodopa or dopamine agonists. Curr Treat Options Neurol. 2001;3:479-493.
24. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord. 2005;20:190-199.